Investment Thesis
Ekso Bionics is deeply unprofitable with a -321.6% net margin and -262.4% operating margin, losing $6.9M on just $2.1M revenue. Revenue is declining 28.6% YoY while the company burns -$2.1M in operating cash flow annually, unsustainable with only $4.0M in cash reserves. While gross margins are healthy at 50.2%, massive operating expenses and the cash burn trajectory indicate fundamental business model challenges requiring urgent strategic restructuring.
Strengths
- Positive gross margin of 50.2% indicates viable unit economics at product level
- Improving net losses YoY (41.8% improvement in diluted EPS) shows cost management progress
- Positive stockholders' equity of $2.1M and cash reserves of $4.0M provide near-term liquidity buffer
Risks
- Severe revenue decline of 28.6% YoY signals deteriorating market demand or execution challenges
- Massive operating losses (-$5.6M) and negative operating cash flow (-$2.1M) are unsustainable long-term
- Quick ratio of 1.03x indicates tight liquidity with limited financial flexibility to fund turnaround or weather disruptions
- Negative cash runway of approximately 2 years at current burn rate creates existential pressure
Key Metrics to Watch
- Quarterly revenue trend to confirm if decline stabilizes or accelerates
- Operating cash flow trajectory and monthly cash burn rate
- Gross margin sustainability and operating expense reduction progress
Financial Metrics
Revenue
2.1M
Net Income
-6.9M
EPS (Diluted)
$-2.04
Free Cash Flow
-2.1M
Total Assets
19.7M
Cash
4.0M
Profitability Ratios
Gross Margin
50.2%
Operating Margin
-262.4%
Net Margin
-321.6%
ROE
-329.4%
ROA
-35.0%
FCF Margin
-99.2%
Balance Sheet & Liquidity
Current Ratio
1.55x
Quick Ratio
1.03x
Debt/Equity
0.96x
Debt/Assets
70.8%
Interest Coverage
-98.56x
Long-term Debt
2.0M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-06T20:19:22.557074 |
Data as of: 2026-03-31 |
Powered by Claude AI